Fennell DA - Search Results

1

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.

Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, Sørensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim U, Kim M, Barrueco J, Tsao AS. Scagliotti GV, et al. Among authors: fennell da. Lancet Respir Med. 2019 Jul;7(7):569-580. doi: 10.1016/S2213-2600(19)30139-0. Epub 2019 May 15. Lancet Respir Med. 2019. PMID: 31103412 Clinical Trial.

2

Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.

Fennell DA, Rudd RM. Fennell DA, et al. Lancet Oncol. 2004 Jun;5(6):354-62. doi: 10.1016/S1470-2045(04)01492-5. Lancet Oncol. 2004. PMID: 15172356 Review.

3

Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.

Fennell DA, C Steele JP, Shamash J, Sheaff MT, Evans MT, Goonewardene TI, Nystrom ML, Gower NH, Rudd RM. Fennell DA, et al. Lung Cancer. 2005 Feb;47(2):277-81. doi: 10.1016/j.lungcan.2004.08.005. Lung Cancer. 2005. PMID: 15639727 Clinical Trial.

4

Prognostic factors in mesothelioma.

Steele JP, Klabatsa A, Fennell DA, Palläska A, Sheaff MT, Evans MT, Shamash J, Rudd RM. Steele JP, et al. Among authors: fennell da. Lung Cancer. 2005 Jul;49 Suppl 1:S49-52. doi: 10.1016/j.lungcan.2005.03.009. Lung Cancer. 2005. PMID: 15894403

5

Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.

Fennell DA, Steele JP, Shamash J, Evans MT, Wells P, Sheaff MT, Rudd RM, Stebbing J. Fennell DA, et al. Cancer. 2007 Jan 1;109(1):93-9. doi: 10.1002/cncr.22366. Cancer. 2007. PMID: 17146783 Free article.

6

Advances in the systemic therapy of malignant pleural mesothelioma.

Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J. Fennell DA, et al. Nat Clin Pract Oncol. 2008 Mar;5(3):136-47. doi: 10.1038/ncponc1039. Nat Clin Pract Oncol. 2008. PMID: 18227828 Review.

7

Translational therapies for malignant pleural mesothelioma.

Belli C, Anand S, Tassi G, Fennell D, Mutti L. Belli C, et al. Expert Rev Respir Med. 2010 Apr;4(2):249-60. doi: 10.1586/ers.10.17. Expert Rev Respir Med. 2010. PMID: 20406091 Review.

8

Small-cell lung cancer.

van Meerbeeck JP, Fennell DA, De Ruysscher DK. van Meerbeeck JP, et al. Among authors: fennell da. Lancet. 2011 Nov 12;378(9804):1741-55. doi: 10.1016/S0140-6736(11)60165-7. Epub 2011 May 10. Lancet. 2011. PMID: 21565397 Review.

9

Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.

Blayney JK, Ceresoli GL, Castagneto B, O'Brien ME, Hasan B, Sylvester R, Rudd R, Steele J, Busacca S, Porta C, Mutti L, O'Byrne KJ, Scullin P, Gaafar R, Baas P, Van Meerbeeck J, Fennell DA. Blayney JK, et al. Among authors: fennell da. Eur J Cancer. 2012 Nov;48(16):2983-92. doi: 10.1016/j.ejca.2012.05.018. Epub 2012 Jun 15. Eur J Cancer. 2012. PMID: 22704893

10

Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.

Fennell DA, McDowell C, Busacca S, Webb G, Moulton B, Cakana A, O'Byrne KJ, Meerbeeck JV, Donnellan P, McCaffrey J, Baas P. Fennell DA, et al. J Thorac Oncol. 2012 Sep;7(9):1466-70. doi: 10.1097/JTO.0b013e318260dfb9. J Thorac Oncol. 2012. PMID: 22895144 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

205 results

Search Page